---
title: "Why the U.S. Is Falling Behind England in the Push to Eliminate Hepatitis C"
id: "stat-news-3-opinion-england-and-other-nations-are-on-the-path-toward-eliminating-hepatitis"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-3-opinion-england-and-other-nations-are-on-the-path-toward-eliminating-hepatitis"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/08/us-hepatitis-c-cure-medication-cost-elimination/?utm_campaign=rss"
published_at: "2026-10-08T08:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Why the U.S. Is Falling Behind England in the Push to Eliminate Hepatitis C
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-3-opinion-england-and-other-nations-are-on-the-path-toward-eliminating-hepatitis
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/08/us-hepatitis-c-cure-medication-cost-elimination/?utm_campaign=rss)
- **Published At:** 2026-10-08T08:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Hepatitis C is a bloodborne viral infection that can progress to chronic liver disease, cirrhosis, and end-stage liver failure; it remains a leading cause of liver transplantation after alcohol-associated liver disease. - Modern direct-acting antiviral medications cure more than **95%** of people with chronic hepatitis C in **8–12 weeks** and have minimal side effects. - Several nations — including **England**, Egypt, and Norway — have mounted coordinated national campaigns that combine expanded testing (including opt-out and community-based approaches) with free or low-cost treatment, producing substantial declines in infections and deaths. - England aims to eliminate hepatitis C by **2030**, has treated **80%** of infections, achieved a **36%** reduction in hepatitis C deaths over the past decade, and reduced prevalence among people who inject drugs from **28.6% in 2015** to **5.2% in 2024**. - In contrast, U.S. progress is lagging: new hepatitis C infections increased from **2013–2021** and were stagnant from **2021–2023**; nearly **70,000** new cases were reported in **2023**, about double the CDC’s annual target. - Although the U.S. has access to the same curative drugs, only about **50%** of Americans with chronic hepatitis C receive medication. Barriers include drug cost history, administrative hurdles (referrals, prior authorizations), primary care shortages, and fragmentation of care. - Stigma related to injection drug use and resistance to harm-reduction strategies impede outreach, testing, and provision of sterile supplies and other preventive services. Fear of judgment also discourages care-seeking. - Treating hepatitis C earlier is cost-saving: the CDC estimates curative therapy can avoid downstream costs (including transplants and chronic disease management) and save nearly **$70,000** in lifetime medical costs per person. - The U.S. has the clinical tools to eliminate hepatitis C but lacks the coordinated political will and system-level changes shown to work in other countries.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/10/08/us-hepatitis-c-cure-medication-cost-elimination/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/08/us-hepatitis-c-cure-medication-cost-elimination/?utm_campaign=rss) [Cancer](https://www.statnews.com/topic/cancer/) [research](https://www.statnews.com/topic/research/) [patients](https://www.statnews.com/topic/patients/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Summit](https://www.statnews.com/stat-summit-boston/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) Opinion[First Opinion](https://www.statnews.com/category/first-opinion/) # England and other nations are on the path toward eliminating hepatitis C. Why not the U.S.? ## The U.S. has a long way to go * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/08/us-hepatitis-c-cure-medication-cost-elimination/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/10/C0078712-Hepatitis_C_viruses_TEM-645x645.jpg) THOMAS DEERINCK, NCMIR/SCIENCE PHOTO LIBRARY By Philip A. Chan, Alan Epstein, and Amy Nunn Oct. 8, 2026 Chan is the chief medical officer at the Rhode Island Public Health Institute and a consultant medical director with the Rhode Island Department of Health. Epstein is a gastroenterologist specializing in hepatology at the Rhode Island Public Health Institute’s Open Door Health clinic. Nunn is the chief executive officer of the Rhode Island Public Health Institute. In September, “Baywatch” star Pamela Anderson [opened up about her hepatitis C diagnosis](https://www.nbcboston.com/entertainment/entertainment-news/pamela-anderson-hepatitis-c-amfar/4011234/) in the 1990s. “It was a death sentence,” she said while accepting the Award of Courage from amfAR, an organization supporting HIV/AIDS research and advocacy. When she was diagnosed, she said, her doctor told her that she might only live another 10 years. Her story is a good reminder of the amount of global progress that has been made in preventing and treating hepatitis C in just the last decade — and how far the U.S. has to go to catch up to our European neighbors. Advertisement Hepatitis C is a serious, bloodborne infectious disease that primarily impacts the liver. While some people can clear the infection on their own, the majority are at major risk of developing chronic, potentially fatal conditions like cirrhosis and end-stage liver disease. Hepatitis C infections are among the most common causes of medically necessary liver transplantations, second only to alcohol-associated liver disease. When Anderson was first diagnosed in the late 1990s, the hepatitis C virus was still relatively novel. It had only [been officially discovered in 1989](https://www.niddk.nih.gov/news/archive/2016/story-discovery-hepatitis-c-from-non-a-non-b-hepatitis-cure), and there were few if any effective treatments available. One could argue she was lucky to have even been diagnosed. Since hepatitis C symptoms can often be delayed or “silent,” many patients — both then and today — go undiagnosed until more serious conditions present more obvious symptoms. Fortunately for Anderson and countless others, the landscape around hepatitis C quickly evolved. One of the more significant medical breakthroughs of the 2000s was the [development and regulatory approval of hepatitis C medications](https://www.cdc.gov/hepatitis-c/treatment/index.html) that have minimal side effects and cure more than 95% of people with chronic disease in just eight to 12 weeks. It’s not an exaggeration to say these once-a-day pills have saved thousands of lives and created a realistic path toward eradicating hepatitis C on a global scale. Advertisement Related Story ![](https://www.statnews.com/wp-content/uploads/2023/06/AdobeStock_330998866-768x432.jpeg) ### [We have a cure for hepatitis C — so why aren’t more people getting treatment?](https://www.statnews.com/2023/06/29/hepatitis-c-cure-access/) Many countries around the world — notably, [England](https://www.bbc.com/news/articles/c75gk620r22o), [Egypt](https://pmc.ncbi.nlm.nih.gov/articles/PMC11357586/), and [Norway](https://www.fhi.no/en/news/2024/norway-is-among-the-first-countries-in-the-world-to-have-achieved-the-global-treatment-target-among-people-diagnosed-with-hepatitis-c/) — have made great strides down that path in recent years. Each country has taken its own public health approach to this issue, but the common thread among successful national campaigns has been a dual focus on ramping up routine testing, particularly among high-risk populations, and increasing access to affordable — or, in many cases, free — medication. England, for example, launched a robust approach to hepatitis C testing, which included implementing [“opt-out” testing policies](https://www.england.nhs.uk/long-read/blood-borne-viruses-opt-out-testing-in-emergency-departments/) for HIV, hepatitis B, and hepatitis C in emergency departments; rolling out [mobile testing vans](https://www.eatg.org/hiv-news/nhs-testing-initiative-to-eliminate-hepatitis-c-in-england-by-2025/) and care teams to traditionally underserved communities; and offering [free at-home testing kits](https://www.england.nhs.uk/2024/04/nhs-expands-one-hour-liver-testing-to-help-detect-and-eliminate-hep-c/) to anyone who requested one. For folks who test positive for the virus, medication is quickly prescribed free of charge through the National Health Service. The strategy is paying off. England, which aims to eliminate the virus by 2030, has already met its goal of treating 80% of its hepatitis C infections. Deaths from the virus have decreased by 36% in the past decade. Among England’s population of people who inject drugs, [just 5.2% had the infection in 2024](https://www.gov.uk/government/news/hepatitis-c-infections-in-people-who-inject-drugs-continue-to-fall), compared with 28.6% in 2015. Here in the United States, while we are seeing some effective plans [deployed at the state level](https://health.ri.gov/sites/g/files/xkgbur1006/files/publications/actionplans/Hepatitis-C-RI-Strategic-Plan-2022.pdf), progress nationally is stalling. Despite having access to the same highly effective medications, the number of new hepatitis C infections [reported across the country](https://www.cdc.gov/hepatitis/php/npr-2025/hep-c-reduce-infections.html) steadily increased from 2013-2021 and remained stagnant between 2021-2023. Nearly 70,000 new cases were reported in 2023, which was double the annual target set by the Centers for Disease Control and Prevention. Like many issues in public health, cost and red tape within the health care system are factors in our nation’s lack of progress. Hepatitis C medications have [historically been expensive](https://www.bostonglobe.com/metro/2016/04/09/for-hepatitis-patients-cure-for-high-drug-prices/j2X4aVi7BEpU5BSL0YV0vN/story.html?event=event12), and even though they’re covered through Medicaid and most commercial insurers, only around 50% of Americans with chronic hepatitis C are medicated. People may go untreated because they were simply never prescribed medication. Others may not have access to a primary care doctor due to [widespread shortages](https://pubmed.ncbi.nlm.nih.gov/40329027/), or they may find themselves overwhelmed by administrative hurdles, including referrals, prior authorizations, insurance requirements, and follow-up appointments in multiple care settings. Advertisement The U.S. also has an [issue with stigma](https://pmc.ncbi.nlm.nih.gov/articles/PMC12700462/). Due in large part to the opioid epidemic, injection drug use is now the [primary risk factor](https://pmc.ncbi.nlm.nih.gov/articles/PMC6698583/) for new hepatitis C infections in the United States. Yet people who use drugs continue to face significant stigma in our health care system and in the broader public policy debate. Resistance to proven harm reduction strategies can make it harder to reach people with testing, sterile supplies, and other preventive services. Plus, fear of judgment can discourage people from seeking care in the first place. These gaps in our system are leaving people behind and [costing our health system billions of dollars](https://www.cdc.gov/nchhstp/whats-new/hepatitis-c-treatment-saves.html). According to the CDC, by avoiding the exorbitant cost of organ transplants and treatment of chronic disease later in life, curative treatment for hepatitis C can save nearly $70,000 in lifetime medical costs per person. Unlike when Pamela Anderson first received her diagnosis, the U.S. today has the tools to cure hepatitis C for good. Other countries around the world are showing this once-ambitious public health goal is very much achievable. If we find the political will to make necessary changes, we can be next. _Philip A. Chan, M.D., is the chief medical officer at the Rhode Island Public Health Institute and a consultant medical director with the Rhode Island Department of Health._ _Alan Epstein, M.D., is a gastroenterologist specializing in hepatology at the Rhode Island Public Health Institute’s Open Door Health clinic in Providence._ _Amy Nunn, Sc.D., is the chief executive officer of the Rhode Island Public Health Institute._ * * * ###### Letter to the editor Have an opinion on this essay? [Submit a letter to the editor](https://www.statnews.com/submit-a-letter-to-the-editor/?subject=England%20and%20other%20nations%20are%20on%20the%20path%20toward%20eliminating%20hepatitis%20C.%20Why%20not%20the%20U.S.?). [global health](https://www.statnews.com/topic/global-health/), [infectious disease](https://www.statnews.com/topic/infectious-disease/), [public health](https://www.statnews.com/topic/public-health/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. Philip A. Chan 1. [](https://www.linkedin.com/in/philipchanmd/ "Linkedin") 1. [](https://www.linkedin.com/in/philipchanmd/ "Linkedin") 2. Alan Epstein 1. [](https://www.linkedin.com/in/alan-epstein-md-25771412/ "Linkedin") 1. [](https://www.linkedin.com/in/alan-epstein-md-25771412/ "Linkedin") 3. Amy Nunn 1. [](https://www.linkedin.com/in/amy-nunn-0b43752b0/ "Linkedin") 1. [](https://www.linkedin.com/in/amy-nunn-0b43752b0/ "Linkedin") ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/First-Opinion-Logo-Black-640x319.png) ### Newsletter The smartest thinkers in life sciences on what's happening — and what's to come Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-1179020747-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down](https://www.statnews.com/2026/10/07/caribou-biosciences-shutting-down-lymphoma-car-t-therapy/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/10/Exon-Skipping-handout-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few](https://www.statnews.com/2026/10/07/muscular-dystrophy-exon-skipping-drugs-novartis-dyne/) 3. ![](https://www.statnews.com/wp-content/uploads/2024/09/IMG_4278-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Merck suffers a setback in Europe over its new Keytruda formulation](https://www.statnews.com/pharmalot/2026/10/07/merck-suffers-setback-in-europe-over-new-keytruda-formulation/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/szy091426_longevity_07-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Can you live longer for $5,500? Longevity clinics are the buzzy new trend at nonprofit hospitals](https://www.statnews.com/2026/10/06/hospitals-longevity-clinics-healthy-aging-wellness-trend/) 5. ![](https://www.statnews.com/wp-content/uploads/2020/01/AdobeStock_194847041-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Justice Department targets drugmakers in new directive on combating white-collar fraud](https://www.statnews.com/pharmalot/2026/10/07/trump-administration-adds-pharma-to-list-priorities-combating-white-collar-fraud/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/TevaPF_Wordpress_CalendarImage-80x80.jpg) The Next Era of Biosimilars: Rewriting the Playbook Virtual Oct 19 ](https://www.statnews.com/event/next-era-of-biosimilars-rewriting-the-playbook/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/ESMORecap_Wordpress_CalendarImage-80x80.jpg) ESMO 2026: The STAT Recap Virtual Oct 29 ](https://www.statnews.com/event/esmo-2026-the-stat-recap/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/09/AdobeStock_127843759-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Momentum is building for a big change to how doctors get paid](
## Related Clinical Research

- [Reflecting on 50 Years of Interleukin-2: Advancements in Immunotherapy and Retrovirology](https://medichelpline.com/clinical-feed/stat-news-2-opinion-50-years-ago-my-colleagues-and-i-pursued-basic-research-science-that.md)
- [GSK wins approval for hepatitis B therapy as biotech news ripples through sector](https://medichelpline.com/clinical-feed/stat-news-0-stat-gsk-picks-up-hep-b-drug-approval.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)
- [Monocyte phenotypes associated with peri‑coronary inflammation in people with and without HIV](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-distinct-monocyte-phenotypes-are-associated-with-peri-coronary-inflammation-in.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.